Pathophysiologically, excessive accumulation of diacylglycerol (DAG), a lipid signal messenger, in pancreatic β-cells has been shown to lead to the insufficiency of insulin secretion. Thus, the regulation of intracellular DAG levels is expected to be an important factor in maintaining β-cell function. The intracellular DAG levels are strictly controlled by DAG kinases (DGKs). We have previously shown that DGKα and γ, type I DGK isoforms, are highly expressed in mouse β-cells, and that DAG accumulation resulting from dysfunction of these DGKs reduces insulin secretion. In the present study, we investigated the effect of type I DGK dysfunction on the regulation of intracellular Ca2+ concentration ([Ca2+]i), which is correlated with insulin secretion, in the β-cell line MIN6B. We also analyzed changes in expression levels of DGKα and γ in β-cells of type 2 diabetes model NSY mice. The amplitude of glucose-induced [Ca2+]i oscillations was increased by 1 μM R59949, a type I DGK inhibitor, and by 10 μM DiC8, a DAG analog. These effects were abolished by Ro31-8220, a protein kinase C (PKC) inhibitor. In contrast, 10 μM R59949 and 100 μM DiC8 suppressed the glucose-induced [Ca2+]i elevation, which was insensitive to Ro31-8220, and furthermore reduced voltage-dependent Ca2+ channel (VDCC) currents, which were measured by patch-clamp recording, implying that DAG accumulation due to type I DGK dysfunction suppresses VDCC, thereby reducing [Ca2+]i in β-cells. Real-time qPCR showed that the expression level of DGKα and γ was lower in islets from NSY mice compared with control mice. Taken together, the results obtained here suggest that DAG accumulation due to type I DGK dysfunction has contradictory dual effect in β-cells depending on the degree of accumulation; mild accumulation PKC-dependently induces a stimulatory effect on insulin secretion, whereas excessive accumulation suppresses it independently of PKC. DGK is likely a key molecule for the progression of type 2 diabetes.

Disclosure

T. Sawatani: None. Y.K. Kaneko: None. T. Ishikawa: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.